E.E. Geduld’s Alnylam Pharmaceuticals ALNY Stock Holding History

E.E. Geduld’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-3,000	Closed	-$241K	–	194
2015 Q3	$241K	Sell	3,000 -4,500	-60%	-$500K	0.23%	92
2015 Q2	$899K	Sell	7,500 -11,250	-60%	-$1.34M	0.56%	27
2015 Q1	$1.96M	Buy	18,750 +8,250	+79%	+$836K	1.31%	8
2014 Q4	$1.02M	Sell	10,500 -2,000	-16%	-$185K	0.55%	26
2014 Q3	$976K	Buy	12,500 +5,000	+67%	+$323K	0.69%	24
2014 Q2	$474K	Buy	+7,500	New	+$446K	0.29%	80

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

E.E. Geduld's ALNY Position: Q4 2015 in Review

E.E. Geduld sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2015, closing a stake of 3,000 shares — an estimated $241K sold.

E.E. Geduld first reported a position in ALNY in Q2 2014 and held it in 6 quarters. The position peaked at $1.96M in Q1 2015. 261 funds tracked by Wall St. Rank hold ALNY as of Q4 2015.

E.E. Geduld reported no remaining Alnylam Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
E.E. Geduld sold 3,000 Alnylam Pharmaceuticals shares in Q4 2015, an estimated $241K.
E.E. Geduld first reported a position in Alnylam Pharmaceuticals in Q2 2014 and held it in 6 quarters.
E.E. Geduld's Alnylam Pharmaceuticals position peaked at $1.96M in Q1 2015.
261 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2015.

Based on E.E. Geduld's 13F filing for Q4 2015, filed 2 Feb 2016.